FAM111A-DT: A Potential Drug Target and Biomarker (G101927204)

Target Name: FAM111A-DT

NCBI ID: G101927204

FAM111A-DT

Other Name(s): FAM111A divergent transcript

FAM111A-DT: A Potential Drug Target and Biomarker

Abstract:

FAM111A-DT, a RNA-protein complex, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This protein plays a crucial role in cellular signaling and has been involved in the development and progression of various diseases.

Introduction:

FAM111A (FAM111A gene) is a non-coding RNA molecule that has been identified in various cellular processes, including cell signaling, DNA replication, and RNA translation. It is a key regulator of gene expression and has been involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

FAM111A-DT, a RNA-protein complex, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This protein plays a crucial role in cellular signaling and has been involved in the development and progression of various diseases.

FAM111A-DT Structure and Function:

FAM111A-DT is a protein complex that consists of the FAM111A RNA molecule and the protein domain of the microtubule-associated protein 2 (MAP2). It is primarily expressed in the brain and plays a role in regulating the expression of various genes in the brain, including genes involved in cell signaling, neurotransmitter synthesis, and cell survival.

FAM111A-DT has been shown to be involved in several cellular processes, including the regulation of microtubule dynamics, the assembly and disassembly of microtubules, and the regulation of gene expression. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Drug Target:

FAM111A-DT has been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in cellular signaling and its role in the development and progression of various diseases make it an attractive target for drug development.

FAM111A-DT has been shown to play a role in the regulation of cell proliferation, apoptosis, and angiogenesis, which are all key processes involved in the development and progression of cancer. It has also been shown to be involved in the regulation of neurotransmitter synthesis and release, which is important for the function of various brain cells.

FAM111A-DT has also been shown to be involved in the regulation of inflammation and immune response, which are important for the development and progression of autoimmune disorders.

Biomarker:

FAM111A-DT has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in cellular signaling and its role in the development and progression of various diseases make it an attractive candidate for biomarker research.

Conclusion:

FAM111A-DT is a RNA-protein complex that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in cellular signaling and its role in the development and progression of various diseases make it an attractive target for drug development. Further research is needed to fully understand the role of FAM111A-DT in cellular processes and its potential as a drug target and biomarker.

Protein Name: FAM111A Divergent Transcript

The "FAM111A-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM111A-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets